A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
Syros Pharmaceuticals
Syros Pharmaceuticals
AstraZeneca
Masonic Cancer Center, University of Minnesota
Northwestern University
Dartmouth-Hitchcock Medical Center
National Institutes of Health Clinical Center (CC)